PO.MCB10.02 · 分子与细胞生物学
长链非编码RNA RFX5-AS1在卵巢癌早期阶段表现出表达上调
Long non-coding RNA RFX5-AS1 exhibits upregulated expression in early stages of ovarian cancer
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
卵巢癌(OC)是全球女性健康面临的重大挑战，导致高发病率和高死亡率。由于卵巢癌无症状，且传统生物标志物(CA125和HE4)在疾病初期往往缺乏足够的敏感性和特异性，其早期检测仍是一个严峻的挑战。长链非编码RNA(lncRNA)因其在肿瘤发生中的调控作用，已成为有前景的分子指标。此前，利用GEPIA数据库进行的生物信息学分析发现，与健康个体相比，RFX5-AS1在卵巢癌中表达上调，提示其作为生物标志物的潜力，并突显其在卵巢癌病理生理学和肿瘤进展中的作用。本研究探讨了RFX5-AS1作为卵巢癌标志物的早期检测潜力，强调需要进一步研究这一lncRNA以改善诊断、预后和治疗。通过定量实时PCR(qRT-PCR)分析了从美国OriGene Technology获取的特征明确的卵巢组织样本中RFX5-AS1的表达水平，这些样本涵盖了各个疾病分期。严格采用管家基因(beta-actin)进行标准化，以确保重复性和准确性。进行统计学分析以评估各分期间的差异表达。RFX5-AS1在早期卵巢癌组织中显著上调，在IIA期(p = 0.0490)和IIB期(p = 0.0113)中观察到表达升高。重要的是，RFX5-AS1的表达在晚期疾病中持续保持较高水平，在IIIB期(p = 0.0156)和IV期(p = 0.0286)中检测到显著升高。这些发现提示，RFX5-AS1不仅在早期可被检测到，而且在后期进展中仍具相关性，突显其作为贯穿整个疾病过程的稳健生物标志物的潜在用途。RFX5-AS1在卵巢癌早期和晚期均持续过表达，突显其作为早期检测和疾病监测可靠生物标志物的前景。将RFX5-AS1纳入诊断流程可提高在现有标志物受限的分期识别卵巢癌的敏感性，从而有助于更早干预并改善患者预后。
查看英文原文 English abstract
Ovarian cancer (OC) is a significant global health challenge to women's health worldwide, leading to high rates of morbidity and mortality. Early detection of OC remains a serious challenge since it is asymptomatic, and the conventional biomarkers (CA125 and HE4) often lack sufficient sensitivity and specificity in the initial stages. Long non-coding RNAs (lncRNAs) have emerged as promising molecular indicators due to their regulatory roles in tumorigenesis. Previously, bioinformatics analysis using the GEPIA database identified the upregulation of RFX5-AS1 in OC compared to healthy individuals, suggesting its potential as a biomarker and highlighting its role in OC pathophysiology and tumor progression. The current study investigated the possibility of early detection potential of RFX5-AS1 as a marker for OC, emphasizing the need for further investigation of this lncRNA to improve diagnosis, prognosis, and therapies. The expression levels of RFX5‑AS1 were analyzed by quantitative real‑time PCR (qRT‑PCR) in well‑characterized ovarian tissue samples obtained from OriGene Technology, USA, encompassing a spectrum of disease stages. Rigorous normalization to housekeeping (beta-actin) was performed to ensure reproducibility and accuracy. Statistical analyses were conducted to evaluate differential expression across stages. RFX5‑AS1 was significantly upregulated in early‑stage ovarian cancer tissues, with elevated expression observed in stage IIA (p = 0.0490) and stage IIB (p = 0.0113). Importantly, RFX5‑AS1 expression remained consistently high in advanced disease, with significant increases detected in stage IIIB (p = 0.0156) and stage IV (p = 0.0286). These findings suggest that RFX5‑AS1 is not only detectable at early stages but also maintains relevance in later progression, underscoring its potential utility as a robust biomarker across the disease continuum. The consistent overexpression of RFX5‑AS1 in both early and late stages of ovarian cancer highlights its promise as a reliable biomarker for early detection and disease monitoring. Incorporation of RFX5‑AS1 into diagnostic workflows may improve sensitivity in identifying OC at stages where current markers are limited, thereby contributing to earlier intervention and improved patient outcomes.
利益披露 Disclosure
A. J. Al Handhali, None.